The Role of Bacterial Superantigens in the Immune Response: From Biology to Cancer Treatment

Mohammad    S.   Hashemzadeh; Behnam    E.G.   Tapeh; Seyed    A.    Mirhosseini
Abstract

Aims: Encouraging results have been indicated preclinically and in patients using the bacterial superantigen. This review article intends to summarize the role of the superantigens that have been recently used in the treatment of cancer. In addition, the vector systems, including lentiviral vectors, adeno-associated vector systems and retroviral vectors that are increasingly being used in basic and applied research, were discussed. Most importantly, the new CRISPR technique has also been discussed in this literature review.
Discussion: More successful therapies can be achieved by manipulating bacterial vector systems through incorporating genes related to the superantigens and cytokines. The products of SAg and cytokine genes contribute to the strong stimulation of the immune system against tumor cells. They bind to MHC II molecules as well as the V beta regions of TCR and lead to the production of IL2 and other cytokines, the activation of antigen-presenting cells and T lymphocytes. Additionally, superantigens can be used to eradicate tumor cells. Better results in cancer treatment can be achieved by transferring superantigen genes and subsequent strong immune stimulation along with other cancer immunotherapy agents.
Conclusion: Superantigens induce the proliferation of T lymphocytes and antigen-presenting cells by binding to MHCII molecules and V beta regions in T cell receptors. Therefore, the presentation of tumor cell antigens is increased. Additionally, the production of important cytokines by T cells and APCs contributes to the stimulation of immune response against tumor cells. The manipulation of bacterial vector systems through incorporating genesrelated to SAgs and other immune response factors is a good strategy for the immune system stimulating and eradicating tumor cells along with other immunotherapy agents.
Keywords: Superantigen, immunotherapy, cancer, T lymphocyte, immune response, lymphocyte.
Graphical Abstract

[1] 
Alouf JE, Müller-Alouf H. Staphylococcal and streptococcal superantigens: Molecular, biological and clinical aspects. Int J Med Microbiol  2003; 292(7-8): 429-40.
[http://dx.doi.org/10.1078/1438-4221-00232 ] [PMID:  12635926] 
[2] 
DeVries AS, Lesher L, Schlievert PM, et al. Staphylococcal toxic shock syndrome 2000-2006: Epidemiology, clinical features, and molecular characteristics. PLoS One  2011; 6(8): e22997.
[http://dx.doi.org/10.1371/journal.pone.0022997 ] [PMID:  21860665] 
[3] 
White J, Herman A, Pullen AM, Kubo R, Kappler JW, Marrack P. The V β-specific superantigen staphylococcal enterotoxin B: Stimulation of mature T cells and clonal deletion in neonatal mice. Cell  1989; 56(1): 27-35.
[http://dx.doi.org/10.1016/0092-8674(89)90980-X ] [PMID:  2521300] 
[4] 
Janeway CA Jr, Yagi J, Conrad PJ, et al. T-cell responses to Mls and to bacterial proteins that mimic its behavior. Immunol Rev  1989; 107(1): 61-88.
[http://dx.doi.org/10.1111/j.1600-065X.1989.tb00003.x ] [PMID:  2522086] 
[5] 
Fleischer B. A conserved mechanism of T lymphocyte stimulation by microbial exotoxins. Microb Pathog  1989; 7(2): 79-83.
[http://dx.doi.org/10.1016/0882-4010(89)90027-2 ] [PMID:  2512465] 
[6] 
Callahan JE, Herman A, Kappler JW, Marrack P. Stimulation of B10.BR T cells with superantigenic staphylococcal toxins. J Immunol  1990; 144(7): 2473-9.
[PMID:  2138648] 
[7] 
Watson AR, Lee WT. Defective T cell receptor-mediated signal transduction in memory CD4 T lymphocytes exposed to superantigen or anti-T cell receptor antibodies. Cell Immunol  2006; 242(2): 80-90.
[http://dx.doi.org/10.1016/j.cellimm.2006.09.008 ] [PMID:  17083922] 
[8] 
Misfeldt ML. Microbial “superantigens”. Infect Immun  1990; 58(8): 2409-13.
[http://dx.doi.org/10.1128/IAI.58.8.2409-2413.1990 ] [PMID:  2196226] 
[9] 
Fleischer B, Schrezenmeier H, Conradt P. T lymphocyte activation by staphylococcal enterotoxins: Role of class II molecules and T cell surface structures. Cell Immunol  1989; 120(1): 92-101.
[http://dx.doi.org/10.1016/0008-8749(89)90177-9 ] [PMID:  2522832] 
[10] 
Mollick JA, Cook RG, Rich RR. Class II MHC molecules are specific receptors for staphylococcus enterotoxin A. Science  1989; 244(4906): 817-20.
[http://dx.doi.org/10.1126/science.2658055 ] [PMID:  2658055] 
[11] 
Baker MD, Acharya KR. Superantigens: Structure, function, and diversity  Am Soc Microbiol .   2007; 2007: pp. 121-35.
[12] 
Papageorgiou AC, Acharya KR. Microbial superantigens: From structure to function. Trends Microbiol  2000; 8(8): 369-75.
[http://dx.doi.org/10.1016/S0966-842X(00)01793-5 ] [PMID:  10920396] 
[13] 
Tripp TJ, McCormick JK, Webb JM, Schlievert PM. The zinc-dependent major histocompatibility complex class II binding site of streptococcal pyrogenic exotoxin C is critical for maximal superantigen function and toxic activity. Infect Immun  2003; 71(3): 1548-50.
[http://dx.doi.org/10.1128/IAI.71.3.1548-1550.2003 ] [PMID:  12595474] 
[14] 
Hâkansson M, Petersson K, Nilsson H, et al. The crystal structure of staphylococcal enterotoxin H: Implications for binding properties to MHC class II and TcR molecules. J Mol Biol  2000; 302(3): 527-37.
[http://dx.doi.org/10.1006/jmbi.2000.4093 ] [PMID:  10986116] 
[15] 
Abrahmsén L, Dohlsten M, Segrén S, Björk P, Jonsson E, Kalland T. Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A. EMBO J  1995; 14(13): 2978-86.
[http://dx.doi.org/10.1002/j.1460-2075.1995.tb07300.x ] [PMID:  7542584] 
[16] 
Fraser JD, Urban RG, Strominger JL, Robinson H. Zinc regulates the function of two superantigens. Proc Natl Acad Sci USA  1992; 89(12): 5507-11.
[http://dx.doi.org/10.1073/pnas.89.12.5507 ] [PMID:  1608962] 
[17] 
Sundström M, Hallén D, Svensson A, Schad E, Dohlsten M, Abrahmsén L. The Co-crystal structure of staphylococcal enterotoxin type A with Zn2+ at 2.7 A resolution. Implications for major histocompatibility complex class II binding. J Biol Chem  1996; 271(50): 32212-6.
[http://dx.doi.org/10.1074/jbc.271.50.32212 ] [PMID:  8943278] 
[18] 
Tiedemann RE, Urban RJ, Strominger JL, Fraser JD. Isolation of HLA-DR1 (staphylococcal enterotoxin A)2 trimers in solution. Proc Natl Acad Sci USA  1995; 92(26): 12156-9.
[http://dx.doi.org/10.1073/pnas.92.26.12156 ] [PMID:  8618863] 
[19] 
Baker M, Gutman DM, Papageorgiou AC, Collins CM, Acharya KR. Structural features of a zinc binding site in the superantigen strepococcal pyrogenic exotoxin A (SpeA1): Implications for MHC class II recognition. Protein Sci  2001; 10(6): 1268-73.
[http://dx.doi.org/10.1110/ps.330101 ] [PMID:  11369867] 
[20] 
Papageorgiou AC, Collins CM, Gutman DM, et al. Structural basis for the recognition of superantigen streptococcal pyrogenic exotoxin A (SpeA1) by MHC class II molecules and T-cell receptors. EMBO J  1999; 18(1): 9-21.
[http://dx.doi.org/10.1093/emboj/18.1.9 ] [PMID:  9878045] 
[21] 
Sundström M, Abrahmsén L, Antonsson P, Mehindate K, Mourad W, Dohlsten M. The crystal structure of staphylococcal enterotoxin type D reveals Zn2+-mediated homodimerization. EMBO J  1996; 15(24): 6832-40.
[http://dx.doi.org/10.1002/j.1460-2075.1996.tb01074.x ] [PMID:  9003758] 
[22] 
Proft T, Moffatt SL, Berkahn CJ, Fraser JD. 
                        Identification and characterization of novel superantigens from 
                        
                            Streptococcus pyogenes
                        
                        .
                     J Exp Med  1999; 189(1): 89-102.
[http://dx.doi.org/10.1084/jem.189.1.89 ] [PMID:  9874566] 
[23] 
Baker MD, Acharya KR. Superantigens: Structure-function relationships. Int J Med Microbiol  2004; 293(7-8): 529-37.
[http://dx.doi.org/10.1078/1438-4221-00298 ] [PMID:  15149028] 
[24] 
Krakauer T. Differential inhibitory effects of interleukin-10, interleukin-4, and dexamethasone on staphylococcal enterotoxin-induced cytokine production and T cell activation. J Leukoc Biol  1995; 57(3): 450-4.
[http://dx.doi.org/10.1002/jlb.57.3.450 ] [PMID:  7884317] 
[25] 
Li H, Llera A, Mariuzza RA. Structure-function studies of T-cell receptor-superantigen interactions. Immunol Rev  1998; 163(1): 177-86.
[http://dx.doi.org/10.1111/j.1600-065X.1998.tb01196.x ] [PMID:  9700510] 
[26] 
Deringer JR, Ely RJ, Stauffacher CV, Bohach GA. Subtype-specific interactions of type C staphylococcal enterotoxins with the T- cell receptor. Mol Microbiol  1996; 22(3): 523-34.
[http://dx.doi.org/10.1046/j.1365-2958.1996.1381506.x ] [PMID:  8939435] 
[27] 
Swaminathan S, Furey W, Pletcher J, Sax M. Crystal structure of staphylococcal enterotoxin B, a superantigen. Nature  1992; 359(6398): 801-6.
[http://dx.doi.org/10.1038/359801a0 ] [PMID:  1436058] 
[28] 
Acharya KR, Passalacqua EF, Jones EY, et al. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1. Nature  1994; 367(6458): 94-7.
[http://dx.doi.org/10.1038/367094a0 ] [PMID:  8107781] 
[29] 
Ohlendorf DH. Structure of Toxic Shock Syndrome Toxin-1.In: Protein Toxin Structure Springer.  1996.
[http://dx.doi.org/10.1007/978-3-662-22352-9_11] 
[30] 
Petersson K, Pettersson H, Skartved NJ, Walse B, Forsberg G. Staphylococcal enterotoxin H induces V α-specific expansion of T cells. J Immunol  2003; 170(8): 4148-54.
[http://dx.doi.org/10.4049/jimmunol.170.8.4148 ] [PMID:  12682246] 
[31] 
Tian XL, Yan Z, Chen J, Zhao WH, Guo W. Clinical application of highly agglutinative staphylococcin in cancer treatment updates of the literature. Eur Rev Med Pharmacol Sci  2016; 20(12): 2718-25.
[PMID:  27383328] 
[32] 
Dohlsten M, Lando PA, Björk P, et al. Immunotherapy of human colon cancer by antibody-targeted superantigens. Cancer Immunol Immunother  1995; 41(3): 162-8.
[http://dx.doi.org/10.1007/BF01521342 ] [PMID:  7553685] 
[33] 
Kominsky SL, Torres BA, Hobeika AC, Lake FA, Johnson HM. Superantigen enhanced protection against a weak tumor-specific melanoma antigen: Implications for prophylactic vaccination against cancer. Int J Cancer  2001; 94(6): 834-41.
[http://dx.doi.org/10.1002/ijc.1551 ] [PMID:  11745486] 
[34] 
Perabo FG, Willert PL, Wirger A, Schmidt DH, Von Ruecker A, Mueller SC. Superantigen-activated mononuclear cells induce apoptosis in transitional cell carcinoma. Anticancer Res  2005; 25(5): 3565-73.
[PMID:  16101181] 
[35] 
Ma W, Yu H, Wang Q, Jin H, Solheim J, Labhasetwar V. A novel approach for cancer immunotherapy: Tumor cells with anchored superantigen SEA generate effective antitumor immunity. J Clin Immunol  2004; 24(3): 294-301.
[http://dx.doi.org/10.1023/B:JOCI.0000025451.41948.94 ] [PMID:  15114060] 
[36] 
Wahlsten JL, Mills CD, Ramakrishnan S. Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells. J Immunol  1998; 161(12): 6761-7.
[PMID:  9862706] 
[37] 
Yi P, Yu H, Ma W, Wang Q, Minev BR. Preparation of murine B7.1-glycosylphosphatidylinositol and transmembrane-anchored staphylococcal enterotoxin. A dual-anchored tumor cell vaccine and its antitumor effect. Cancer  2005; 103(7): 1519-28.
[http://dx.doi.org/10.1002/cncr.20943 ] [PMID:  15739200] 
[38] 
Ma W, Yu H, Wang Q, Bao J, Yan J, Jin H. In vitro biological activities of transmembrane superantigen staphylococcal enterotoxin A fusion protein.
                     Cancer Immunol Immunother  2004; 53(2): 118-24.
[http://dx.doi.org/10.1007/s00262-003-0437-0 ] [PMID:  14574492] 
[39] 
Plautz GE, Barnett GH, Miller DW, et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg  1998; 89(1): 42-51.
[http://dx.doi.org/10.3171/jns.1998.89.1.0042 ] [PMID:  9647171] 
[40] 
Hansson J, Ohlsson L, Persson R, et al. Genetically engineered superantigens as tolerable antitumor agents. Proc Natl Acad Sci USA  1997; 94(6): 2489-94.
[http://dx.doi.org/10.1073/pnas.94.6.2489 ] [PMID:  9122222] 
[41] 
Dohlsten M, Hedlund G, Akerblom E, Lando PA, Kalland T. Monoclonal antibody-targeted superantigens: A different class of anti- tumor agents. Proc Natl Acad Sci USA  1991; 88(20): 9287-91.
[http://dx.doi.org/10.1073/pnas.88.20.9287 ] [PMID:  1924393] 
[42] 
Dohlsten M, Abrahmsén L, Björk P, et al. Monoclonal antibody- superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy. Proc Natl Acad Sci USA  1994; 91(19): 8945-9.
[http://dx.doi.org/10.1073/pnas.91.19.8945 ] [PMID:  8090750] 
[43] 
Takemura S, Kudo T, Asano R, et al. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma. Cancer Immunol Immunother  2002; 51(1): 33-44.
[http://dx.doi.org/10.1007/s00262-001-0245-3 ] [PMID:  11845258] 
[44] 
Erlandsson E, Andersson K, Cavallin A, et al. Identification of the antigenic epitopes in staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy. J Mol Biol  2003; 333(5): 893-905.
[http://dx.doi.org/10.1016/j.jmb.2003.09.009 ] [PMID:  14583188] 
[45] 
Yu QT, Meng ZB. Treatment of advanced breast cancer with a combination of highly agglutinative staphylococcin and vinorelbine-based chemotherapy. Eur Rev Med Pharmacol Sci  2016; 20(16): 3465-8.
[PMID:  27608908] 
[46] 
Cohen SG, Dzury DS, Michelini FJ. 
                        Immune responses to 
                        
                            Staphylococcus aureus
                        
                         antigens.
                     J Infect Dis  1958; 103(1): 61-6.
[http://dx.doi.org/10.1093/infdis/103.1.61 ] [PMID:  13575862] 
[47] 
Zonggui JXQQX. Effect of highly agglutinative staphylococcin on MDR gene expression and NK cell activity in patients with advanced hepatoma. Chin J Clin Oncol  1998; 1998: 7.
[48] 
Kawaguchi-Nagata K, Okamura H, Shoji K, Kanagawa H, Semma M, Shinagawa K. 
                        Immunomodulating activities of staphylococcal enterotoxins. I. Effects on 
                        
                            in vivo
                        
                         antibody responses and contact sensitivity reaction.
                     Microbiol Immunol  1985; 29(3): 183-93.
[http://dx.doi.org/10.1111/j.1348-0421.1985.tb00818.x ] [PMID:  3874343] 
[49] 
Yuanjiao Q. The therapeutic effects of highly agglutinative Staphylococcin combined with Cisplatin in the treatment of patients with malignant pleural effusion. J Basic Clin Oncol  2010; 2010: 1.
[50] 
Mu P. Clinical research on ultrasonically guided intrahepatic injections of HAS in interventional treatment of liver carcinomas. J Balkan Union Oncol In:   2016; 21(6): 1394-7.
[51] 
Jiemin Z. The therapeutic effect of malignant ascites with improved central venous catheter combined with 5-Fluorouracil and highly agglutinative Staphylococcin. J Basic Clin Oncol  2011; 2011: 4.
[52] 
Wang W, Sun X, Lu L, Zheng JB, Tian Y, Wang W. Cytotoxicity of lymphocytes activated by superantigen toxic-shock-syndrome toxin-1 against colorectal cancer LoVo cells. Mol Cell Biochem  2013; 376(1-2): 1-9.
[http://dx.doi.org/10.1007/s11010-013-1561-6 ] [PMID:  23340976] 
[53] 
Wang. Hypoxia microenvironment regulates immunotherapy effect of TSST-1 on CEA positive colon cancer LoVo cells. Zhongguo Zhongliu Shengwu Zhiliao Zazhi  2011; 2011: 6.
[54] 
Wang W. Packaging and identification of recombinant retrovirus dual cancer-specific expressing superantigen of TSST-1 gene. J Xi'an Jiaotong Univ Med Sci 2011; 5: 3.
[55] 
Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science  1990; 248(4956): 705-11.
[http://dx.doi.org/10.1126/science.2185544 ] [PMID:  2185544] 
[56] 
Dohlsten M, Sundstedt A, Björklund M, Hedlund G, Kalland T. Superantigen-induced cytokines suppress growth of human colon- carcinoma cells. Int J Cancer  1993; 54(3): 482-8.
[http://dx.doi.org/10.1002/ijc.2910540321 ] [PMID:  8509223] 
[57] 
Dohlsten M, Hansson J, Ohlsson L, Litton M, Kalland T. 
                        Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc Natl Acad Sci USA  1995; 92(21): 9791-5.
[http://dx.doi.org/10.1073/pnas.92.21.9791 ] [PMID:  7568219] 
[58] 
Jiang Y-Q, Wang HR, Li HP, Hao HJ, Zheng YL, Gu J. Targeting of hepatoma cell and suppression of tumor growth by a novel 12mer peptide fused to superantigen TSST-1. Mol Med  2006; 12(4-6): 81-7.
[http://dx.doi.org/10.2119/2006-00011.Jiang ] [PMID:  16953561] 
[59] 
Si S, Sun Y, Li Z, et al. Gene therapy by membrane-expressed superantigen for α-fetoprotein-producing hepatocellular carcinoma. Gene Ther  2006; 13(22): 1603-10.
[http://dx.doi.org/10.1038/sj.gt.3302823 ] [PMID:  16855617] 
[60] 
Bashraheel SS, AlQahtani AD, Rashidi FB, et al. Studies on vascular response to full superantigens and superantigen derived peptides: Possible production of novel superantigen variants with less vasodilation effect for tolerable cancer immunotherapy. Biomed Pharmacother  2019; 2019: 115108905.
[http://dx.doi.org/10.1016/j.biopha.2019.108905 ] [PMID:  31060004] 
[61] 
Commons RJ, Smeesters PR, Proft T, Fraser JD, Robins-Browne R, Curtis N. Streptococcal superantigens: Categorization and clinical associations. Trends Mol Med  2014; 20(1): 48-62.
[http://dx.doi.org/10.1016/j.molmed.2013.10.004 ] [PMID:  24210845] 
[62] 
Forsberg G, Skartved NJ, Wallén-Ohman M, et al. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity. J Immunother  2010; 33(5): 492-9.
[http://dx.doi.org/10.1097/CJI.0b013e3181d75820 ] [PMID:  20463598] 
[63] 
Nathan A, Shahar M. Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy. Google Patents, 2019.
[64] 
Sun J, Zhao L, Teng L, et al. Solid tumor-targeted infiltrating cytotoxic T lymphocytes retained by a superantigen fusion protein. PLoS One  2011; 6(2): e16642.
[http://dx.doi.org/10.1371/journal.pone.0016642 ] [PMID:  21311755] 
[65] 
Hedlund G, Dohlsten M, Lando PA, Kalland T. Staphylococcal enterotoxins direct and trigger CTL killing of autologous HLA-DR+ mononuclear leukocytes and freshly prepared leukemia cells. Cell Immunol  1990; 129(2): 426-34.
[http://dx.doi.org/10.1016/0008-8749(90)90218-G ] [PMID:  2383900] 
[66] 
Fuller CL, Braciale VL. Selective induction of CD8+ cytotoxic T lymphocyte effector function by staphylococcus enterotoxin B. J Immunol  1998; 161(10): 5179-86.
[PMID:  9820488] 
[67] 
Proft T, Fraser JD. Streptococcal superantigens.In: Superantigens and Superallergens  Karger Publishers: Switzerland.   2007; pp. 1-23.
[http://dx.doi.org/10.1159/000100851] 
[68] 
Arad G, Levy R, Hillman D, Kaempfer R. Superantigen antagonist protects against lethal shock and defines a new domain for T- cell activation. Nat Med  2000; 6(4): 414-21.
[http://dx.doi.org/10.1038/74672 ] [PMID:  10742148] 
[69] 
Arad G, Levy R, Nasie I, et al. Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. PLoS Biol  2011; 9(9): e1001149.
[http://dx.doi.org/10.1371/journal.pbio.1001149 ] [PMID:  21931534] 
[70] 
Fleischer B, Necker A, Leget C, Malissen B, Romagne F. Reactivity of mouse T-cell hybridomas expressing human Vbeta gene segments with staphylococcal and streptococcal superantigens. Infect Immun  1996; 64(3): 987-94.
[http://dx.doi.org/10.1128/IAI.64.3.987-994.1996 ] [PMID:  8641811] 
[71] 
Li P-L, Tiedemann RE, Moffat SL, Fraser JD. The superantigen streptococcal pyrogenic exotoxin C (SPE-C) exhibits a novel mode of action. J Exp Med  1997; 186(3): 375-83.
[http://dx.doi.org/10.1084/jem.186.3.375 ] [PMID:  9236189] 
[72] 
Li Y, Li H, Dimasi N, et al. Crystal structure of a superantigen bound to the high-affinity, zinc-dependent site on MHC class II. Immunity  2001; 14(1): 93-104.
[http://dx.doi.org/10.1016/S1074-7613(01)00092-9 ] [PMID:  11163233] 
[73] 
Kasper KJ, Xi W, Rahman AK, et al. Molecular requirements for MHC class II α-chain engagement and allelic discrimination by the bacterial superantigen streptococcal pyrogenic exotoxin C. J Immunol  2008; 181(5): 3384-92.
[http://dx.doi.org/10.4049/jimmunol.181.5.3384 ] [PMID:  18714010] 
[74] 
Hobohm U. Fever and cancer in perspective. Cancer Immunol Immunother  2001; 50(8): 391-6.
[http://dx.doi.org/10.1007/s002620100216 ] [PMID:  11726133] 
[75] 
Linnebacher M, Maletzki C, Klier U, Klar E. Bacterial immunotherapy of gastrointestinal tumors. Langenbecks Arch Surg  2012; 397(4): 557-68.
[http://dx.doi.org/10.1007/s00423-011-0892-6 ] [PMID:  22189906] 
[76] 
Zacharski LR, Sukhatme VP. Coley’s toxin revisited: Immunotherapy or plasminogen activator therapy of cancer? J Thromb Haemost  2005; 3(3): 424-7.
[http://dx.doi.org/10.1111/j.1538-7836.2005.01110.x ] [PMID:  15748226] 
[77] 
Linnebacher M, Maletzki C, Emmrich J, Kreikemeyer B. Lysates of S. pyogenes serotype M49 induce pancreatic tumor growth delay by specific and unspecific antitumor immune responses. J Immunother  2008; 31(8): 704-13.
[http://dx.doi.org/10.1097/CJI.0b013e3181829f62 ] [PMID:  18779749] 
[78] 
Brown EL, et al. 
                        Treatment of metastatic equine melanoma with a plasmid DNA vaccine encoding 
                        
                            streptococcus pyogenes
                        
                         EMM55 protein.
                     J Equine Vet Sci  2014; 34(5): 704-8.
[http://dx.doi.org/10.1016/j.jevs.2013.11.012] 
[79] 
Proft T, Fraser JD. Streptococcal superantigens: Biological properties and potential role in disease In: Streptococcus pyogenes: Basic biology to clinical manifestations  University of Oklahoma Health Sciences Center,.  2016.
[80] 
Mingozzi F, High KA. Immune responses to AAV vectors: Overcoming barriers to successful gene therapy. Blood  2013; 122(1): 23-36.
[http://dx.doi.org/10.1182/blood-2013-01-306647 ] [PMID:  23596044] 
[81] 
Escors D, Breckpot K. Lentiviral vectors in gene therapy: Their current status and future potential. Arch Immunol Ther Exp (Warsz)  2010; 58(2): 107-19.
[http://dx.doi.org/10.1007/s00005-010-0063-4 ] [PMID:  20143172] 
[82] 
Wold WS, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther  2013; 13(6): 421-33.
[http://dx.doi.org/10.2174/1566523213666131125095046 ] [PMID:  24279313] 
[83] 
Felberbaum RS. The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors. Biotechnol J  2015; 10(5): 702-14.
[http://dx.doi.org/10.1002/biot.201400438 ] [PMID:  25800821] 
[84] 
Hitchman RB, Locanto E, Possee RD, King LA. Optimizing the baculovirus expression vector system. Methods  2011; 55(1): 52-7.
[http://dx.doi.org/10.1016/j.ymeth.2011.06.011 ] [PMID:  21945427] 
[85] 
Vanrell L, Di Scala M, Blanco L, et al. Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancer. Mol Ther  2011; 19(7): 1245-53.
[http://dx.doi.org/10.1038/mt.2011.37 ] [PMID:  21364542] 
[86] 
Sayroo R, Nolasco D, Yin Z, et al. Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther  2016; 23(1): 18-25.
[http://dx.doi.org/10.1038/gt.2015.89 ] [PMID:  26270885] 
[87] 
Li L-H, He J, Hua D, Guo ZJ, Gao Q. 
                        Lentivirus-mediated inhibition of Med19 suppresses growth of breast cancer cells 
                        
                            in vitro
                        
                        .
                     Cancer Chemother Pharmacol  2011; 68(1): 207-15.
[http://dx.doi.org/10.1007/s00280-010-1468-9 ] [PMID:  20890603] 
[88] 
Jia XQ, Cheng HQ, Qian X, et al. Lentivirus-mediated overexpression of microRNA-199a inhibits cell proliferation of human hepatocellular carcinoma. Cell Biochem Biophys  2012; 62(1): 237-44.
[http://dx.doi.org/10.1007/s12013-011-9263-8 ] [PMID:  21847633] 
[89] 
Sicard F, Gayral M, Lulka H, Buscail L, Cordelier P. Targeting miR-21 for the therapy of pancreatic cancer. Mol Ther  2013; 21(5): 986-94.
[http://dx.doi.org/10.1038/mt.2013.35 ] [PMID:  23481326] 
[90] 
Negri DR, Bona R, Michelini Z, et al. Transduction of human antigen-presenting cells with integrase-defective lentiviral vector enables functional expansion of primed antigen-specific CD8(+) T cells. Hum Gene Ther  2010; 21(8): 1029-35.
[http://dx.doi.org/10.1089/hum.2009.200 ] [PMID:  20210625] 
[91] 
Shiau A-L, Teo ML, Chen SY, et al. Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin. BMC Cancer  2010; 10(1): 245.
[http://dx.doi.org/10.1186/1471-2407-10-245 ] [PMID:  20509975] 
[92] 
Ranjbar S, Hashemzadeh Ms, Nikkhoi SK, Farasat A. Selective suppression of tumor cells by a tumor-specific bicistronic lentiviral vector. Turk J Biol  2016; 40(6): 1289-94.
[http://dx.doi.org/10.3906/biy-1512-53] 
[93] 
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc  2013; 8(11): 2281-308.
[http://dx.doi.org/10.1038/nprot.2013.143 ] [PMID:  24157548] 
[94] 
Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science  2014; 343(6166): 84-7.
[http://dx.doi.org/10.1126/science.1247005 ] [PMID:  24336571] 
[95] 
Noori-Daloii MR, Ebadi N. Pharmacogenomics and cancer stem cells. Med Sci J Islamic Azad Univ  2015; 25(1): 1-15.
[96] 
Young KM, Phelan JD, Webster DE, et al. Crispr-Cas9 genetic screens uncover Ab cell receptor-Myd88 superpathway in diffuse large B cell lymphoma. Hematol Oncol  2017; 35: 25-5.
[http://dx.doi.org/10.1002/hon.2437_4] 
[97] 
Xue W, Chen S, Yin H, et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature  2014; 514(7522): 380-4.
[http://dx.doi.org/10.1038/nature13589 ] [PMID:  25119044] 
Cite As
Current Cancer Therapy Reviews

The Role of Bacterial Superantigens in the Immune Response: From Biology to Cancer Treatment

Abstract

Graphical Abstract
